Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | BDKRB1 | P46663 | 12/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183509 | 0.83 | CA1 (0.56) | NPC1HPGDRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3126366 | 0.82 | SLC6A3 (0.58) | SLC6A3SLC6A4BDKRB1SLC6A2 | |
| SCHEMBL15761732 | 0.81 | CA1 (0.60) | NPC1HPGDRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL15755350 | 0.81 | KDM4E (0.48) | NPC1HPGDRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL15761758 | 0.81 | KDM4E (0.48) | NPC1HPGDRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL5061628 | 0.79 | SLC6A3 (0.61) | SLC6A3SLC6A4BDKRB1SMN1; SMN2SLC6A2 | |
| SCHEMBL1715126 | 0.79 | MAPT (0.60) | SLC6A3SLC6A4NPC1HPGDKMT2A | |
| SCHEMBL8871967 | 0.78 | SLC6A3 (0.69) | SLC6A3SLC6A4BDKRB1SLC6A2 | |
| SCHEMBL3112718 | 0.78 | SLC6A3 (0.69) | SLC6A3SLC6A4BDKRB1KMT2ASLC6A2 | |
| SCHEMBL29979869 | 0.78 | SLC6A3 (0.69) | SLC6A3SLC6A4BDKRB1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327001-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2022-04-13 | — | — | EP | disclosed |
| CN-108349875-B | Compound having BLT inhibitory activity and composition for preventing or treating inflammatory disease comprising the same as active ingredient | 东国大学校产学协力团 | 2021-08-27 | — | — | CN | disclosed |
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-08-02 | — | — | US | disclosed |
| EP-3327001-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | SLC6A3 4540/4885SLC6A4 3712/4885BDKRB1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.